A Phase 2, Open Label Extension Study To Investigate The Long Term Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease

Trial Profile

A Phase 2, Open Label Extension Study To Investigate The Long Term Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs PF 6649751 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Dec 2017 Status changed from active, no longer recruiting to discontinued.
    • 23 Nov 2017 This trial has been discontinued in Spain (End date: 2017-09-22).
    • 09 Nov 2017 This trial has been discontinued in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top